Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology

Brian P. Hobbs, Pedro C. Barata, Yada Kanjanapan, Channing Paller, Jane Perlmutter, Gregory R. Pond, Tatiana M. Prowell, Eric H. Rubin, Lesley K. Seymour, Nolan A. Wages, Timothy A. Yap, David Feltquate, Elizabeth Garrett-Mayer, William Grossman, David S. Hong, S. Percy Ivy, Lillian L. Siu, Steven A. Reeves, Gary Rosner

Research output: Contribution to journalArticle

Abstract

Traditionally, drug development has evaluated dose, safety, activity, and comparative benefit in a sequence of phases using trial designs and endpoints specifically devised for each phase. Innovations in drug development seek to consolidate the phases and rapidly expand accrual with "seamless" trial designs. Although consolidation and rapid accrual may yield efficiencies, widespread use of seamless first-in-human (FiH) trials without careful consideration of objectives, statistical analysis plans, or trial oversight raises concerns. A working group formed by the National Cancer Institute convened to consider and discuss opportunities and challenges for such trials as well as encourage responsible use of these designs. We reviewed all abstracts presented at American Society of Clinical Oncology annual meetings from 2010 to 2017 for FiH trials enrolling at least 100 patients. We identified 1786 early-phase trials enrolling 57 559 adult patients. Fifty-one of the trials (2.9%) investigated 50 investigational new drugs, were seamless, and accounted for 14.6% of the total patients. The seamless trials included a median of 3 (range = 1-13) expansion cohorts. The overall risk of clinically significant treatment-related adverse events (grade 3-4) was 49.1% (range = 0.0-100%), and seven studies reported at least one toxic death. Rapid expansion of FiH trials may lead to earlier drug approval and corresponding widespread patient access to active therapeutics. Nevertheless, seamless designs must adhere to established ethical, scientific, and statistical standards. Protocols should include prospectively planned analyses of efficacy in disease- or biomarker-defined cohorts of sufficient rigor to support accelerated approval.

Original languageEnglish (US)
Pages (from-to)118-128
Number of pages11
JournalJournal of the National Cancer Institute
Volume111
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Pharmaceutical Preparations
Investigational Drugs
Drug Approval
National Cancer Institute (U.S.)
Poisons
Biomarkers
Safety
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Seamless Designs : Current Practice and Considerations for Early-Phase Drug Development in Oncology. / Hobbs, Brian P.; Barata, Pedro C.; Kanjanapan, Yada; Paller, Channing; Perlmutter, Jane; Pond, Gregory R.; Prowell, Tatiana M.; Rubin, Eric H.; Seymour, Lesley K.; Wages, Nolan A.; Yap, Timothy A.; Feltquate, David; Garrett-Mayer, Elizabeth; Grossman, William; Hong, David S.; Ivy, S. Percy; Siu, Lillian L.; Reeves, Steven A.; Rosner, Gary.

In: Journal of the National Cancer Institute, Vol. 111, No. 2, 01.02.2019, p. 118-128.

Research output: Contribution to journalArticle

Hobbs, BP, Barata, PC, Kanjanapan, Y, Paller, C, Perlmutter, J, Pond, GR, Prowell, TM, Rubin, EH, Seymour, LK, Wages, NA, Yap, TA, Feltquate, D, Garrett-Mayer, E, Grossman, W, Hong, DS, Ivy, SP, Siu, LL, Reeves, SA & Rosner, G 2019, 'Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology', Journal of the National Cancer Institute, vol. 111, no. 2, pp. 118-128. https://doi.org/10.1093/jnci/djy196
Hobbs, Brian P. ; Barata, Pedro C. ; Kanjanapan, Yada ; Paller, Channing ; Perlmutter, Jane ; Pond, Gregory R. ; Prowell, Tatiana M. ; Rubin, Eric H. ; Seymour, Lesley K. ; Wages, Nolan A. ; Yap, Timothy A. ; Feltquate, David ; Garrett-Mayer, Elizabeth ; Grossman, William ; Hong, David S. ; Ivy, S. Percy ; Siu, Lillian L. ; Reeves, Steven A. ; Rosner, Gary. / Seamless Designs : Current Practice and Considerations for Early-Phase Drug Development in Oncology. In: Journal of the National Cancer Institute. 2019 ; Vol. 111, No. 2. pp. 118-128.
@article{cd26928d2b7c44e6bc2579b3599584bd,
title = "Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology",
abstract = "Traditionally, drug development has evaluated dose, safety, activity, and comparative benefit in a sequence of phases using trial designs and endpoints specifically devised for each phase. Innovations in drug development seek to consolidate the phases and rapidly expand accrual with {"}seamless{"} trial designs. Although consolidation and rapid accrual may yield efficiencies, widespread use of seamless first-in-human (FiH) trials without careful consideration of objectives, statistical analysis plans, or trial oversight raises concerns. A working group formed by the National Cancer Institute convened to consider and discuss opportunities and challenges for such trials as well as encourage responsible use of these designs. We reviewed all abstracts presented at American Society of Clinical Oncology annual meetings from 2010 to 2017 for FiH trials enrolling at least 100 patients. We identified 1786 early-phase trials enrolling 57 559 adult patients. Fifty-one of the trials (2.9{\%}) investigated 50 investigational new drugs, were seamless, and accounted for 14.6{\%} of the total patients. The seamless trials included a median of 3 (range = 1-13) expansion cohorts. The overall risk of clinically significant treatment-related adverse events (grade 3-4) was 49.1{\%} (range = 0.0-100{\%}), and seven studies reported at least one toxic death. Rapid expansion of FiH trials may lead to earlier drug approval and corresponding widespread patient access to active therapeutics. Nevertheless, seamless designs must adhere to established ethical, scientific, and statistical standards. Protocols should include prospectively planned analyses of efficacy in disease- or biomarker-defined cohorts of sufficient rigor to support accelerated approval.",
author = "Hobbs, {Brian P.} and Barata, {Pedro C.} and Yada Kanjanapan and Channing Paller and Jane Perlmutter and Pond, {Gregory R.} and Prowell, {Tatiana M.} and Rubin, {Eric H.} and Seymour, {Lesley K.} and Wages, {Nolan A.} and Yap, {Timothy A.} and David Feltquate and Elizabeth Garrett-Mayer and William Grossman and Hong, {David S.} and Ivy, {S. Percy} and Siu, {Lillian L.} and Reeves, {Steven A.} and Gary Rosner",
year = "2019",
month = "2",
day = "1",
doi = "10.1093/jnci/djy196",
language = "English (US)",
volume = "111",
pages = "118--128",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Seamless Designs

T2 - Current Practice and Considerations for Early-Phase Drug Development in Oncology

AU - Hobbs, Brian P.

AU - Barata, Pedro C.

AU - Kanjanapan, Yada

AU - Paller, Channing

AU - Perlmutter, Jane

AU - Pond, Gregory R.

AU - Prowell, Tatiana M.

AU - Rubin, Eric H.

AU - Seymour, Lesley K.

AU - Wages, Nolan A.

AU - Yap, Timothy A.

AU - Feltquate, David

AU - Garrett-Mayer, Elizabeth

AU - Grossman, William

AU - Hong, David S.

AU - Ivy, S. Percy

AU - Siu, Lillian L.

AU - Reeves, Steven A.

AU - Rosner, Gary

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Traditionally, drug development has evaluated dose, safety, activity, and comparative benefit in a sequence of phases using trial designs and endpoints specifically devised for each phase. Innovations in drug development seek to consolidate the phases and rapidly expand accrual with "seamless" trial designs. Although consolidation and rapid accrual may yield efficiencies, widespread use of seamless first-in-human (FiH) trials without careful consideration of objectives, statistical analysis plans, or trial oversight raises concerns. A working group formed by the National Cancer Institute convened to consider and discuss opportunities and challenges for such trials as well as encourage responsible use of these designs. We reviewed all abstracts presented at American Society of Clinical Oncology annual meetings from 2010 to 2017 for FiH trials enrolling at least 100 patients. We identified 1786 early-phase trials enrolling 57 559 adult patients. Fifty-one of the trials (2.9%) investigated 50 investigational new drugs, were seamless, and accounted for 14.6% of the total patients. The seamless trials included a median of 3 (range = 1-13) expansion cohorts. The overall risk of clinically significant treatment-related adverse events (grade 3-4) was 49.1% (range = 0.0-100%), and seven studies reported at least one toxic death. Rapid expansion of FiH trials may lead to earlier drug approval and corresponding widespread patient access to active therapeutics. Nevertheless, seamless designs must adhere to established ethical, scientific, and statistical standards. Protocols should include prospectively planned analyses of efficacy in disease- or biomarker-defined cohorts of sufficient rigor to support accelerated approval.

AB - Traditionally, drug development has evaluated dose, safety, activity, and comparative benefit in a sequence of phases using trial designs and endpoints specifically devised for each phase. Innovations in drug development seek to consolidate the phases and rapidly expand accrual with "seamless" trial designs. Although consolidation and rapid accrual may yield efficiencies, widespread use of seamless first-in-human (FiH) trials without careful consideration of objectives, statistical analysis plans, or trial oversight raises concerns. A working group formed by the National Cancer Institute convened to consider and discuss opportunities and challenges for such trials as well as encourage responsible use of these designs. We reviewed all abstracts presented at American Society of Clinical Oncology annual meetings from 2010 to 2017 for FiH trials enrolling at least 100 patients. We identified 1786 early-phase trials enrolling 57 559 adult patients. Fifty-one of the trials (2.9%) investigated 50 investigational new drugs, were seamless, and accounted for 14.6% of the total patients. The seamless trials included a median of 3 (range = 1-13) expansion cohorts. The overall risk of clinically significant treatment-related adverse events (grade 3-4) was 49.1% (range = 0.0-100%), and seven studies reported at least one toxic death. Rapid expansion of FiH trials may lead to earlier drug approval and corresponding widespread patient access to active therapeutics. Nevertheless, seamless designs must adhere to established ethical, scientific, and statistical standards. Protocols should include prospectively planned analyses of efficacy in disease- or biomarker-defined cohorts of sufficient rigor to support accelerated approval.

UR - http://www.scopus.com/inward/record.url?scp=85061609297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061609297&partnerID=8YFLogxK

U2 - 10.1093/jnci/djy196

DO - 10.1093/jnci/djy196

M3 - Article

C2 - 30561713

AN - SCOPUS:85061609297

VL - 111

SP - 118

EP - 128

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 2

ER -